Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00379353 · ClinicalTrials.gov registry record · Phase 2
The Effects of Thalidomide on Symptom Clusters
A Phase 2 study of Advanced Cancers, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00379353 is a Phase 2 study of Advanced Cancers that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 32 participants, below the 67-participant average among 10 other Advanced Cancers trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00379353, a Phase 2 study of Advanced Cancers, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if thalidomide can improve symptoms such as pain, fatigue,anxiety, poor appetite, depression, and sleep problems in patients with advanced cancer.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Thalidomide
Study Locations (1)
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00379353
The ClinicalTrials.gov registry entry for NCT00379353 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 67-participant average among 10 other Advanced Cancers trials with a reported enrollment target (52% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancers appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00379353 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00379353 about?
NCT00379353 is a clinical study titled "The Effects of Thalidomide on Symptom Clusters". The goal of this clinical research study is to learn if thalidomide can improve symptoms such as pain, fatigue,anxiety, poor appetite, depression, and sleep problems in patients with advanced cancer.
What is the current status of trial NCT00379353?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2006-09. Estimated completion is 2013-01.
What conditions does trial NCT00379353 study?
This clinical trial studies the following conditions: Advanced Cancers.
What interventions are being tested in trial NCT00379353?
The interventions under investigation include: Placebo (DRUG), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00379353?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00379353 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
The Effects of Ginseng on Cancer-Related Fatigue
ACTIVE NOT RECRUITING · Phase 1
-
Study of Vemurafenib, Carboplatin, and Paclitaxel
COMPLETED · Phase 1
-
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.